Literature DB >> 20472718

Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis.

Masaki Shimizu1, Tadafumi Yokoyama, Keiko Yamada, Hisashi Kaneda, Hideo Wada, Taizo Wada, Tomoko Toma, Kazuhide Ohta, Yoshihito Kasahara, Akihiro Yachie.   

Abstract

OBJECTIVES: To compare the pro-inflammatory cytokine profiles and the cytokine kinetics in patients with secondary macrophage activation syndrome (MAS) due to systemic-onset juvenile idiopathic arthritis (s-JIA) and in both active and inactive disease states of s-JIA (but no MAS), with those demonstrated in EBV-induced haemophagocytic lymphohistiocytosis (HLH) and Kawasaki disease (KD), and to investigate the significance of IL-18 in the pathogenesis of s-JIA.
METHODS: Five patients with MAS complicating s-JIA (MAS/s-JIA), 10 with HLH due to EBV infection (EBV-HLH), 22 with KD and 28 healthy controls were analysed. Cytokine concentrations (IL-18, IL-6, neopterin and TNF-alpha receptor Types I and II) were quantified in serum by ELISA. Results were compared with clinical features of MAS/s-JIA, including ferritin concentrations.
RESULTS: Serum IL-18 concentrations in MAS/s-JIA patients were significantly higher than those in EBV-HLH or KD patients (P < 0.05). Serum IL-6 concentrations in KD patients were significantly higher than those in EBV-HLH or MAS/s-JIA patients. Serum neopterin concentrations in EBV-HLH patients were significantly higher than those in MAS/s-JIA or KD patients. Serum IL-18 correlated positively with the following measurements of disease activity: CRP, ferritin, lactate dehydrogenase and other cytokines (P < 0.05). Serum concentrations of IL-18 in s-JIA patients remained elevated in the inactive phase of disease, whereas clinical parameters and other cytokines normalized.
CONCLUSIONS: IL-18 may be an important mediator in s-JIA. Although serum Il-18 concentrations correlated with markers of the disease activity, IL-18 concentrations remained elevated even when other markers of disease activity normalized. Serum IL-18 concentration may be a promising indicator of the disease activity. The cytokine release pattern in MAS/HLH is different among patients with different aetiologies. Monitoring the cytokine profile, including IL-18, may be useful for differentiation of MAS/HLH and evaluation of disease activity in s-JIA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472718     DOI: 10.1093/rheumatology/keq133

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  76 in total

1.  Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome.

Authors:  Maria F Ibarra; Marisa Klein-Gitelman; Elaine Morgan; Maria Proytcheva; Christine Sullivan; Gabrielle Morgan; Lauren M Pachman; Maurice R G O'Gorman
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

Review 2.  What do cytokine profiles tell us about subsets of juvenile idiopathic arthritis?

Authors:  Rolando Cimaz; Davide Moretti; Ilaria Pagnini; Achille Marino; Luca Cantarini; Gabriele Simonini
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 3.  Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis.

Authors:  Lehn K Weaver; Edward M Behrens
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

4.  Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor.

Authors:  Yujuan Zhang; Saloni Gupta; Alexandra Ilstad-Minnihan; Sashi Ayyangar; Arielle D Hay; Virginia Pascual; Norman T Ilowite; Claudia Macaubas; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2018-06-19       Impact factor: 3.969

5.  Paediatric rheumatic disease: Diagnosing macrophage activation syndrome in systemic JIA.

Authors:  Sebastiaan J Vastert; Berent J Prakken
Journal:  Nat Rev Rheumatol       Date:  2014-09-09       Impact factor: 20.543

6.  The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness.

Authors:  Keith A Sikora; Ndate Fall; Sherry Thornton; Alexei A Grom
Journal:  Arthritis Rheum       Date:  2012-11

7.  Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.

Authors:  Lehn K Weaver; Edward M Behrens
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-02-07

8.  Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.

Authors:  Zachary Junga; Rodger Stitt; Christopher Tracy; Michael Keith
Journal:  BMJ Case Rep       Date:  2017-08-21

Review 9.  Adult-onset Still's disease with macrophage activation syndrome diagnosed and treated based on cytokine profiling: a case-based review.

Authors:  Ken Goda; Tsuneaki Kenzaka; Masahiko Hoshijima; Akihiro Yachie; Hozuka Akita
Journal:  Rheumatol Int       Date:  2019-09-20       Impact factor: 2.631

10.  Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.

Authors:  Grant S Schulert; Shima Yasin; Brenna Carey; Claudia Chalk; Thuy Do; Andrew H Schapiro; Ammar Husami; Allen Watts; Hermine I Brunner; Jennifer Huggins; Elizabeth D Mellins; Esi M Morgan; Tracy Ting; Bruce C Trapnell; Kathryn A Wikenheiser-Brokamp; Christopher Towe; Alexei A Grom
Journal:  Arthritis Rheumatol       Date:  2019-10-01       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.